<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17709" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Antipsychotic Medications</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chokhawala</surname>
            <given-names>Krutika</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Stevens</surname>
            <given-names>Lee</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Krutika Chokhawala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lee Stevens declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17709.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">First-generation antipsychotics are dopamine receptor antagonists (DRA) and are known as typical antipsychotics. Second-generation antipsychotics are serotonin-dopamine antagonists and are also known as atypical antipsychotics. This activity outlines the indications, mechanism of action, safe administration, adverse effects, contraindications, monitoring, and toxicity of antipsychotic medications.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate indications for the various antipsychotic medications.</p></list-item><list-item><p>Summarize the mechanism of action of both first and second-generation antipsychotics.</p></list-item><list-item><p>Outline the appropriate follow-up and monitoring of antipsychotic drug therapy.</p></list-item><list-item><p>Review some interprofessional team strategies for improving care coordination and communication to advance appropriate clinical outcomes with antipsychotic therapy to treat indicated conditions leading to optimal patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17709&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17709">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17709.s2" sec-type="Indications">
        <title>Indications</title>
        <p>First-generation antipsychotics are dopamine receptor antagonists (DRA) and are known as typical antipsychotics. They include phenothiazines (trifluoperazine, perphenazine, prochlorperazine, acetophenazine, triflupromazine, mesoridazine), butyrophenones (haloperidol), thioxanthenes (thiothixene, chlorprothixene), dibenzoxazepines (loxapine), dihydroindoles&#x000a0;(molindone), and diphenylbutylpiperidines (pimozide).<xref ref-type="bibr" rid="article-17709.r1">[1]</xref><xref ref-type="bibr" rid="article-17709.r2">[2]</xref><xref ref-type="bibr" rid="article-17709.r3">[3]</xref></p>
        <p>Second-generation antipsychotics are serotonin-dopamine antagonists and are also known as atypical antipsychotics. The Food and Drug Administration (FDA) has approved 12 atypical antipsychotics as of the year 2016. They are risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, paliperidone, asenapine, lurasidone, iloperidone, cariprazine, brexpiprazole, and clozapine.<xref ref-type="bibr" rid="article-17709.r4">[4]</xref></p>
        <p>
<bold>Indications</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Schizophrenia and Schizoaffective disorders:&#x000a0;First and second-generation antipsychotics (except clozapine) are indicated for the treatment of an acute episode of psychoses and maintenance therapy of schizophrenia and schizoaffective disorders. First-generation antipsychotics are better for treating positive symptoms of schizophrenia, e.g., hallucinations, delusions, among others. They also decrease the risk of a repeat episode of psychosis. Second-generation antipsychotics treat both positive symptoms and negative symptoms of schizophrenia, e.g.,&#x000a0; withdrawal, ambivalence, among others, and are known to&#x000a0;reduce relapse rates.<xref ref-type="bibr" rid="article-17709.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Acute Mania: First-generation antipsychotics are effective in the treatment of acute mania with psychotic symptoms. All second-generation antipsychotics except clozapine can also be used as a treatment of symptoms of acute mania. Antipsychotics are used with mood stabilizers like lithium, valproic acid, or carbamazepine initially, and then after symptoms stabilize can be gradually decreased and withdrawn.</p>
          </list-item>
          <list-item>
            <p>Major Depressive Disorder with Psychotic features: First or second-generation antipsychotics, along with an antidepressant, is the treatment of choice for depression with psychotic features. Olanzapine and fluoxetine, as a combination therapy, have FDA approval for treatment-resistant depression.</p>
          </list-item>
          <list-item>
            <p>Delusional Disorder: First-generation antipsychotics are indicated in the treatment of delusional disorder and paranoia associated with personality disorders.</p>
          </list-item>
          <list-item>
            <p>Severe Agitation: Severely agitated, irritable, hostile, and hyperactive patients can be treated with a short-term course of first-generation antipsychotics irrespective of the etiology of the behavioral disturbance. Second-generation antipsychotics can also be used for treating acute agitation. Antipsychotics can also be used in children with severe autism exhibiting behavioral disturbances though repeatedly giving antipsychotics is not preferred. Risperidone and olanzapine are useful for controlling aggression in children.</p>
          </list-item>
          <list-item>
            <p>Tourette Disorder: Haloperidol and pimozide are the antipsychotics most commonly used for this syndrome. Tourette disorder is an off-label indication for second-generation antipsychotics.</p>
          </list-item>
          <list-item>
            <p>Borderline Personality Disorder: This type of&#x000a0;personality disorder can have symptoms of psychosis and paranoia. Both first and second-generation antipsychotics are used for the treatment of these symptoms.</p>
          </list-item>
          <list-item>
            <p>Dementia and Delirium:&#x000a0;A low dose of high potency first-generation antipsychotics like haloperidol is recommended for the treatment of agitation in delirium and dementia. It is essential to use caution in elderly patients as the antimuscarinic effects can cause significant adverse effects in this population. Second-generation antipsychotics can also be used for treating behavioral disturbances in dementia. Off-Label use of second-generation antipsychotics is acquired immunodeficiency syndrome-related dementia.</p>
          </list-item>
          <list-item>
            <p>Substance-induced psychotic disorder:&#x000a0;In cases of severe psychosis secondary to substance use, antipsychotics can be used to control agitation symptoms. Caution is necessary when using first-generation antipsychotics in alcohol withdrawal and phencyclidine intoxication.</p>
          </list-item>
          <list-item>
            <p>Childhood Schizophrenia: Recent studies have shown the benefit of clozapine in treating early-onset schizophrenia.</p>
          </list-item>
        </list>
        <p>
<bold>Other Indications</bold>
</p>
        <p>Huntington disease, Parkinson disease, Lesch-Nyhan syndrome, pervasive developmental disorder are some&#x000a0;other conditions where antipsychotics are an option though it is not the primary drug of choice.</p>
        <p>
<bold>Clozapine </bold>
</p>
        <p>This drug is the agent of choice when the patient has failed multiple trials of standard antipsychotic therapies. Clozapine is also useful in the treatment of tardive dyskinesia. Indications for the use of clozapine include treatment-resistant mania, severe psychotic features, obsessive-compulsive disorder, pervasive developmental disorders, childhood autism, Parkinson disease, Huntington disease, and suicidal patient with schizophrenia or schizoaffective disorder.</p>
      </sec>
      <sec id="article-17709.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The first-generation antipsychotics work by inhibiting dopaminergic neurotransmission; their effectiveness is best when they block about 72% of the D2 dopamine receptors in the brain. They also have noradrenergic, cholinergic, and histaminergic blocking action.</p>
        <p>Second-generation antipsychotics work by blocking D2 dopamine receptors as well as serotonin receptor antagonist action. 5-HT2A subtype of serotonin receptor is most commonly involved.</p>
      </sec>
      <sec id="article-17709.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>First-Generation Antipsychotics</bold>
</p>
        <p>All dopamine receptor antagonists are available and can be administered in oral form. Except for thioridazine, pimozide, and molindone, all other first-generation antipsychotics can also be given parenterally. Haloperidol and fluphenazine can be delivered in long-acting depot parenteral form.</p>
        <p>
<bold>Second-Generation Antipsychotics</bold>
</p>
        <p>These can be administered in oral or parenteral forms. Risperidone, olanzapine, aripiprazole, and paliperidone are available as extended-release or long-acting injectable forms. Clozapine, asenapine, and olanzapine are available in the sublingual formulation.</p>
      </sec>
      <sec id="article-17709.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>First-generation antipsychotics (FGAs) are associated with significant extrapyramidal side effects. Anticholinergic adverse effects like dry mouth, constipation, urinary retention are common with low potency dopamine receptor antagonists like chlorpromazine, thioridazine. The action of H1 histamine blocking by first-generation antipsychotics causes sedation. Chlorpromazine is the most sedating, while fluphenazine, haloperidol, and pimozide are less sedating. First-generation antipsychotics can also lower the seizure threshold, and chlorpromazine and thioridazine are more epileptogenic than others. Haloperidol can cause abnormal heart rhythm, ventricular arrhythmia, torsades de pointes, and even sudden death if injected intravenously. Other FGAs can cause prolongation of QTc interval, prolonged atrial and ventricular contraction, and other cardiac conduction abnormalities. Thioridazine has an FDA-backed warning for sudden cardiac death. Low-potency FGAs, like chlorpromazine or thioridazine, commonly cause orthostatic hypotension. This adverse effect caused by alpha-adrenergic block usually occurs&#x000a0;when starting treatment, and patients often develop a tolerance. It is important to avoid treating hypotension with epinephrine. Leukopenia, thrombocytopenia, and blood dyscrasia are rare side effects of treatment with FGAs. Increased serum prolactin concentrations along with galactorrhea, breast enlargement, amenorrhea, impotence in men, and anorgasmia in women are known adverse effects due to the action of the dopamine receptor block in the tuberoinfundibular tract. Allergic dermatitis and photosensitivity can occur with chlorpromazine. Chlorpromazine is also associated with blue-gray skin discoloration and benign pigmentation of the lens and cornea. Thioridazine can cause retinal pigmentation, which can continue even after discontinuing the drug.<xref ref-type="bibr" rid="article-17709.r6">[6]</xref><xref ref-type="bibr" rid="article-17709.r7">[7]</xref><xref ref-type="bibr" rid="article-17709.r8">[8]</xref></p>
        <p>Neuroleptic malignant syndrome is a rare but fatal adverse effect that can occur at any time&#x000a0;during treatment with FGAs. The onset of symptoms is over 24 to 72 hours with increased temperature, severe muscular rigidity, confusion, agitation, elevation in white blood cell count, elevated creatinine phosphokinase concentrations, elevated liver enzymes, myoglobinuria, and acute renal failure. The antipsychotic should be immediately discontinued, and dantrolene 0.8 to 2.5 mg/kg every 6 hours up to 10 mg per day is the drug of choice. Adequate hydration, cooling, and there should be close monitoring of vital signs and serum electrolytes. Though the risk of neuroleptic malignant syndrome is higher with first-generation antipsychotics, second-generation antipsychotics also cause this adverse&#x000a0;effect.</p>
        <p>Second-generation antipsychotics (SGAs) have a decreased risk of extrapyramidal side effects as compared to first-generation antipsychotics. SGAs are associated with significant weight gain and the development of metabolic syndrome. The FDA recommends monitoring personal and family history of diabetes mellitus, dyslipidemia, weight, and height, waist circumference, blood pressure, fasting plasma glucose, and fasting lipid profile for all patients. Risperidone is associated with dizziness, anxiety, sedation, and extrapyramidal side effects. Paliperidone can cause temperature sensitivity to hot or cold temperatures and QTc prolongation. Olanzapine has been associated most frequently with weight gain, increased appetite, and somnolence. Quetiapine is the least likely to cause extrapyramidal side effects. The most common side effects of quetiapine are somnolence, orthostatic hypotension, and dizziness. Ziprasidone has almost no weight gain but can cause prolongation of QTc. Aripiprazole is the most common side effect of agitation, headache, and akathisia-like restlessness.</p>
        <p>Asenapine can cause an increase in serum prolactin concentrations, weight gain, and prolongation of QTc. Clozapine can cause hypersalivation, tachycardia, hypotension, and anticholinergic side effects. Clozapine is unusual in that it suppresses dyskinesia. Clozapine can cause clinically important agranulocytosis, leukopenia, and therefore requires monitoring of white blood cells and absolute neutrophil count. The FDA guidelines indicate monitoring absolute neutrophil count weekly for the first six months and, if normal, can be monitored every two weeks after that. Treatment with clozapine should be discontinued if absolute neutrophil count drops below 1000 cells per cubic millimeter or below 500 cells per cubic millimeter in those with benign ethnic neutropenia. Clozapine can also cause the rare side effect of cardiomyopathy and myocarditis.</p>
        <p>FDA boxed warning: Observational studies suggest that similar to second-generation antipsychotics, treatment with first-generation antipsychotics may increase mortality risk in elderly patients with dementia-related psychosis.</p>
        <p>Larger&#x000a0;doses of antipsychotics increase the risk of adverse drug effects.</p>
      </sec>
      <sec id="article-17709.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>First-generation antipsychotics are contraindicated in the following situations:</p>
        <list list-type="order">
          <list-item>
            <p>History of severe allergy</p>
          </list-item>
          <list-item>
            <p>Use of central nervous system (CNS) depressants like barbiturates, benzodiazepines, opioids</p>
          </list-item>
          <list-item>
            <p>With anticholinergic medication like scopolamine or the use of phencyclidine</p>
          </list-item>
          <list-item>
            <p>Severe cardiac abnormalities</p>
          </list-item>
          <list-item>
            <p>History of seizure disorder</p>
          </list-item>
          <list-item>
            <p>Narrow-angle glaucoma or prostatic hypertrophy</p>
          </list-item>
          <list-item>
            <p>History of or ongoing tardive dyskinesia</p>
          </list-item>
        </list>
        <p>Second-generation antipsychotics carry the FDA boxed warning of increased incidence of stroke in elderly patients with dementia. The recommendation is to avoid the use of second-generation antipsychotics along with other drugs that prolong the QTc interval.</p>
        <p>Antipsychotics should be avoided during pregnancy, especially in the first trimester, and should be used only if the benefits outweigh the risks of treatment. Antipsychotics are secreted in breast milk, and it is advisable to avoid breastfeeding.</p>
      </sec>
      <sec id="article-17709.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Some antipsychotics can be monitored for a therapeutic range in the plasma. It is recommended to monitor plasma concentrations at a trough, at a minimum of 12 hours after the prior dose, and best at 20 to 24 hours after the last dose. Most antipsychotics do not have a well-defined dose-response curve.&#x000a0;</p>
        <p>Haloperidol has a therapeutic range of 2 to 15 ng/ml, chlorpromazine has a range of 30 to 100 ng/ml, and perphenazine has a range of 0.8 to 2.4 ng/ml.</p>
        <p>Clozapine shows a better treatment response at a plasma concentration of 350 micrograms per milliliter or higher.</p>
      </sec>
      <sec id="article-17709.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Antipsychotics are widely used medications for a variety of mental health disorders. While effective, these drugs do&#x000a0;have many potential side effects. Healthcare workers, working as an interprofessional team, need to be aware of the adverse effects because they can seriously affect the quality of life. To avoid the metabolic effects of these drugs, the patient needs to receive information regarding lifestyle changes. Regular exercise, discontinuation of smoking, and eating a healthy diet are essential. Also, at each clinic visit, the patient's body weight, blood cholesterol, blood sugar,&#x000a0;and&#x000a0;blood pressure should be&#x000a0;recorded. If the patient is on clozapine, then regular monitoring of the white cell count is required. Only through strict monitoring can the high morbidity of these drugs be limited.<xref ref-type="bibr" rid="article-17709.r9">[9]</xref><xref ref-type="bibr" rid="article-17709.r10">[10]</xref><xref ref-type="bibr" rid="article-17709.r5">[5]</xref></p>
        <p>When the clinician initiates therapy, they should explain the treatment to the patient. Nursing can reiterate this education, answer questions, and assess patient progress and adherence to subsequent visits. Lack of drug adherence can be a significant cause of treatment failure. The pharmacist needs to check for all potential drug-drug interactions and verify appropriate dosing. A board-certified psychiatric pharmacist can also consult on the case with the clinician, offering possible alternatives if treatment does not progress as hoped, e.g., recommend a long-acting dosage form. With these interprofessional interactions, antipsychotic therapy can achieve optimal outcomes for the patient. [Level 5]</p>
      </sec>
      <sec id="article-17709.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17709&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17709">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17709/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17709">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17709.s10">
        <title>References</title>
        <ref id="article-17709.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drummond</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>McCleary</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Freiheit</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Molnar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalziel</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Miyagishima</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Silvius</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Antidepressant and antipsychotic prescribing in primary care for people with dementia.</article-title>
            <source>Can Fam Physician</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>64</volume>
            <issue>11</issue>
            <fpage>e488</fpage>
            <page-range>e488-e497</page-range>
            <pub-id pub-id-type="pmid">30429194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17709.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jennings</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Guerin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Foley</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Development of a tool for monitoring the prescribing of antipsychotic medications to people with dementia in general practice: a modified eDelphi consensus study.</article-title>
            <source>Clin Interv Aging</source>
            <year>2018</year>
            <volume>13</volume>
            <fpage>2107</fpage>
            <page-range>2107-2117</page-range>
            <pub-id pub-id-type="pmid">30425465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17709.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faden</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Citrome</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-24</page-range>
            <pub-id pub-id-type="pmid">30407873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17709.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haddad</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Correll</surname>
                <given-names>CU</given-names>
              </name>
            </person-group>
            <article-title>The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.</article-title>
            <source>Ther Adv Psychopharmacol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>8</volume>
            <issue>11</issue>
            <fpage>303</fpage>
            <page-range>303-318</page-range>
            <pub-id pub-id-type="pmid">30344997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17709.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yazici</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>S Cilli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yazici</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Baysan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ince</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bosgelmez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bilgic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aslan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Erol</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy.</article-title>
            <source>Clin Pract Epidemiol Ment Health</source>
            <year>2017</year>
            <volume>13</volume>
            <fpage>92</fpage>
            <page-range>92-103</page-range>
            <pub-id pub-id-type="pmid">29081826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17709.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ross</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tudhope</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vasudev</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Can We Improve Physical Health Monitoring for Patients Taking Antipsychotics on a Mental Health Inpatient Unit?</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>447</fpage>
            <page-range>447-453</page-range>
            <pub-id pub-id-type="pmid">30113352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17709.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crouse</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Alastanos</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Bozymski</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Toscano</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Dysphagia with second-generation antipsychotics: A case report and review of the literature.</article-title>
            <source>Ment Health Clin</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>56</fpage>
            <page-range>56-64</page-range>
            <pub-id pub-id-type="pmid">29955499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17709.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lozupone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>La Montagna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Urso</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Piccininni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sardone</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dibello</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Giannelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Solfrizzi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Greco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Daniele</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Quaranta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Seripa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bellomo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Logroscino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Panza</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy for the treatment of depression in patients with alzheimer's disease: a treatment-resistant depressive disorder.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>8</issue>
            <fpage>823</fpage>
            <page-range>823-842</page-range>
            <pub-id pub-id-type="pmid">29726758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17709.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brodaty</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aerts</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jessop</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cations</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chenoweth</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Popovic</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Heffernan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hilmer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sachdev</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Draper</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Antipsychotic Deprescription for Older Adults in Long-term Care: The HALT Study.</article-title>
            <source>J Am Med Dir Assoc</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>19</volume>
            <issue>7</issue>
            <fpage>592</fpage>
            <page-range>592-600.e7</page-range>
            <pub-id pub-id-type="pmid">29941156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17709.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pathak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Duff</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Antipsychotic use in older adults: Canadian best practices.</article-title>
            <source>Nurse Pract</source>
            <year>2018</year>
            <month>Jun</month>
            <day>11</day>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>50</fpage>
            <page-range>50-55</page-range>
            <pub-id pub-id-type="pmid">29757837</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
